Posterior reversible encephalopathy syndrome: A neurologic phenomenon in cancer patients

Current Oncology Reports

Volumn 16, Issue 5, 2014, Pages

  Le, Eileen M ^a   Loghin, Monica E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Chemotherapy; Fluid attenuated inversion recovery; Hypertension; Immunosuppressants; Neuro oncology; Neurologic; Oncology; Posterior reversible encephalopathy syndrome; Seizures; White matter edema

Indexed keywords

ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; CANCER PATIENT; CANCER THERAPY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FOCAL EPILEPSY; HEADACHE; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PATHOGENESIS; POSTERIOR PARIETAL CORTEX; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; SEIZURE; TONIC CLONIC SEIZURE; VISUAL DISORDER; VISUAL IMPAIRMENT; WHITE MATTER; MALIGNANT HYPERTENSION; METHODOLOGY; NEOPLASM; REVIEW;

BRAIN EDEMA; HUMANS; HYPERTENSION, MALIGNANT; NEOPLASMS; NEUROIMAGING; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 84894634639     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0383-3     Document Type: Article

References (80)

1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. (Pubitemid 26067737)
2. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320-7. (Pubitemid 47309666)
3. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043-9. (Pubitemid 351954864)
4. Lamy C, Oppenheim C, Meder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging. 2004;14(2):89-96. (Pubitemid 38391815)
5. Yasuhara T, Tokunaga K, Hishikawa T, et al. Posterior reversible encephalopathy syndrome. J Clin Neurosci. 2011;18:406-9.
6. •• Li Y, Gor D, Walicki D, et al. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome. J Stroke CerebrovascDis. 2012;21(8):873-82. This is a retrospective single-center case series which identifies clinical and neuroimaging features, as well as various pathophysiologic causes of PRES.
7. Tsukamoto S, Takeuchi M, Kawajiri C, et al. Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy. Int J Hematol. 2012;95:204-8.
8. Bhatt A, Farooq MU, Majid A, Kassab M. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol. 2009;5(3):163-9.
9. • Ni J, Zhou LX, Hao HL, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging. 2011;21:219-24. This is a retrospective single-center case series which identifies clinical and neuroimaging features of PRES.
10. Iwama M, Takahashi H, Takagi R, Hiraoka M. Permanent bilateral cortical blindness due to reversible posterior leukoencephalopathy syndrome. J Nippon Med Sch. 2011;78:184-8.
11. • Liman TG, Bohner G, Heuschmann PU, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol. 2012;259: 155-64. This is a retrospective multicenter case series which identifies clinical and neuroimaging features of PRES.
12. Mueller-Mang C, Mang T, Pirker A, et al. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance? Neuroradiology. 2009;51:373-83.
13. Munoz J, Kumar V, Hamilton J, et al. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol. 2013;31(20):360-3.
14. Hart C, Kinney MO, McCarron MO. Posterior reversible encephalopathy syndrome and oral methotrexate. Clin Neurol Neurosurg. 2012;114:725-7.
15. Fugate JE, Claasseen DO, Cloft HJ. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427-32.
16. •• Hugonnet E, Da Ines D, Boby H, et al. Posterior reversible encephalopathy syndrome (PRES): features on CT and MR imaging. Diagn Interv Imaging. 2013;94:45-52. This is a review article which identifies various neuroimaging features in different clinical settings.
17. Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long term follow-up. J Neurol Neurosurg Psychiatry. 2010;81:773-7.
18. Burrus TM, Mandrekar J, Wijdicks EM, et al. Renal failure and posterior reversible encephalopathy syndrome in patients with thrombotic thrombocytopenic purpura. Arch Neurol. 2010;67(7):831-4.
19. Patejdl R, Borchert K, Pagumbke H, et al. Posterior reversible encephalopathy syndrome (PRES): an unusual primary manifestation of a diffuse large B-cell lymphoma. Clin Neurol Neurosurg. 2011;113:819-21.
20. Stubgen JP. Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy. J Neurol Sci. 2012;321:35-8.
21. Seet RCS, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. Q J Med. 2012;105:69-75.
22. Chen YH, Huang CH. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine. Clin Breast Cancer. 2012;12(3):222-5.
23. Aradillas E, Arora R, Gasperino J. Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther. 2011;36:529-36.
24. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35(2):83-90. (Pubitemid 40343439)
25. Rajasekhar A, George Jr TJ. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist. 2007;12(11):1332-5. (Pubitemid 350232606)
26. Abali H, Eren OO, Dizdar O, et al. Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. Leuk Lymphoma. 2005;46(12):1825-8. (Pubitemid 43203120)
27. Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18(3):608-9. (Pubitemid 46359652)
28. Moris G, Ribacoba R, Gonzalez C. Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine. J Neurol. 2007;254(4):534-5. (Pubitemid 46786705)
29. Koopman M, Muller EW, Punt CJ. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum. 2008;51(9):1425-6.
30. Kwon EJ, Kim SW, Kim KK, Seo HS, Kim do Y. A case of gemcitabine and Cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat. 2009;41(1):53-5.
31. Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol. 2007;25(33):5320-1. (Pubitemid 350232266)
32. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006;24(28):e48.
33. Connolly RM, Doherty CP, Beddy P, O'Byrne K. Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer. 2007;56(3):459-63. (Pubitemid 46679083)
34. Haefner MD, Siciliano RD, Widmer LA, Vogel Wigger BM, Frick S. Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie. 2007;30(3):138-40. (Pubitemid 46384544)
35. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411-7. (Pubitemid 30487503)
36. Adams Jr HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research inter-disciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115(20):e478-534.
37. Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol. 2001;24(5):361-4.
38. Hammerstrom AE, Howell J, Gulbis A, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88:301-5.
39. Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer. 2009;8(3):163-5.
40. Ozcan C,Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980-2. discussion 980-2.
41. Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122(1):128-34. (Pubitemid 36819347)
42. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant. 1995;15(2):247-53.
43. Shah-Khan F, Pinedo D, Shah P. Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review. Oncol Rev. 2007;1(3):152-61.
44. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10(1):86-91.
45. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet. 1994;344(8921):519-21. (Pubitemid 24261573)
46. Sanders AB. Hypertensive emergencies. Am Fam Physician. 1991;44(5):1767-74.
47. Marinella MA, Markert RJ. Reversible posterior leukoencephalopathy syndrome associated with anticancer drugs. Intern Med J. 2008;39: 826-34.
48. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-10. (Pubitemid 351240781)
49. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23(36):9130-7.
50. Cossaart N, SantaCruz KS, Preston D, Johnson P, Skikne BS. Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature. Bone Marrow Transplant. 2003;31(1):57-60. (Pubitemid 36181823)
51. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271-8. (Pubitemid 46095398)
52. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-24. (Pubitemid 43854967)
53. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77(1):72-6. (Pubitemid 39108801)
54. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475-8. (Pubitemid 44547561)
55. Pruitt A, Graus F, Rosenfeld M. Neurological complications of transplantation: part I: hematopoietic cell transplantation. Neurohospitalist. 2013;3(1):24-38.
56. Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant. 1991;8(5):393-401.
57. Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 2004;25(2):261-9. (Pubitemid 38235306)
58. Zimmer WE, Hourihane JM, Wang HZ, Schriber JR. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 1998;19(4):601-8. discussion 609-10.
59. Furukawa M, Terae S, Chu BC, Kaneko K, Kamada H, Miyasaka K. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging. Neuroradiology. 2001;43(8):615-21. (Pubitemid 32755681)
60. Siddiqui TS, Haq IU, Rehman B, et al. Posterior reversible encephalopathy syndrome (PRES). J Coll Physicians Surg Pak. 2012;22(3):168-70.
61. Naqi R, Azeemuddin M. Posterior reversible encephalopathy syndrome. J Pak Med Assoc. 2012;62(7):657-60.
62. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006;27(10):2179-90. (Pubitemid 44788652)
63. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246(5):339-46. (Pubitemid 29261421)
64. Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000;21(7):1199-206. (Pubitemid 30655653)
65. Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001;77(903):24-8. (Pubitemid 32055944)
66. Lunardi N, Saraceni E, Boccagni P. Posterior reversible encephalopathy syndrome in the intensive care unit after liver transplant: A comparison of our experience with the existing literature. Minerva Anestesiol. 2012;78(7):847-50.
67. Di Nisio M, Soesan M, Otten HM. Endothelial damage of the internal carotid artery after chemoradiotherapy of the neck for a Hodgkin lymphoma. Thromb Haemost. 2007;97(2):315-6. (Pubitemid 46592154)
68. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038-48. (Pubitemid 34663453)
69. Sibai BM. Medical disorders in pregnancy, including hypertensive diseases. Curr Opin Obstet Gynecol. 1990;2(1):13-22. (Pubitemid 20249140)
70. Ito T, Sakai T, Inagawa S, Utsu M, Bun T. MR angiography of cerebral vasospasm in preeclampsia. AJNR Am J Neuroradiol. 1995;16(6):1344-6.
71. Bakshi R, Bates VE, Mechtler LL, Kinkel PR, Kinkel WR. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia. 1998;39(3):295-9. (Pubitemid 28141310)
72. Demirel I, Ozer AB, Bayar MK, et al. Anesthesia and intensive care management in a pregnant woman with PRES: a case report. Case Rep Anesthesiol. 2012. doi:10.1155/2012/745939.
73. Erdogan FF, Ozkan S. A rare entity in ED: Posterior reversible encephalopathy. Am J Emerg Med. 2099;2012(30):e1-3.
74. Andrews P, Azoulay E, Antonelli M, et al. Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury. Intensive Care Med. 2006;32(3):380-90. (Pubitemid 43289646)
75. Andrews P, Azoulay E, Antonelli M, et al. Year in review in intensive care medicine, 2004. III. Outcome, ICU organisation, scoring, quality of life, ethics, psychological problems and communication in the ICU, immunity and hemodynamics during sepsis, pediatric and neonatal critical care, experimental studies. Intensive Care Med. 2005;31(3):356-72.
76. Striano P, Striano S, Totora F, et al. Clinical spectrum and critical care management of posterior reversible encephalopathy syndrome (PRES). Med Sci Monit. 2005;11(11):549-53.
77. Finsterer J, Schlager T, Kopsa W, Wild E. Nitroglycerin-aggravated pre-eclamptic posterior reversible encephalopathy syndrome (PRES). Neurology. 2003;61(5):715-6. (Pubitemid 37082619)
78. 2+ antagonist nimodipine. Neuroscience. 2000;101(1):101-14.
79. Rosetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922-30.
80. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology. 2007;69(9):894-7. (Pubitemid 47329589)